Display search results for ** instead (26 products)

Showing 1-10 of 26

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.

USD 450.00

USD 337.50 save 25 %

11 Jul 2014  |  Global

Will Virtual CROs and Integrated Business Models Rule the Road

Insights into the innovative steps taken by CROs and pharmaceutical companies in the race for excellence and low-cost trials

This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on September 3, 2014, discusses Thermo Fisher Scientifics divestment of laboratory equipment company Cole-Parmer to GTCR, the increasing use of large animal biotechnology in human health applications, the collaboration of Life Technologies and RainTree Oncology Services, the agreement between Ventana and Quintile...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 4, 2014, discusses Roches collaboration with Foundation Medicine, Novartis potential anti-aging drug, and DNA Electronics; acquisition of nanoMR, Inc.

USD 500.00

USD 375.00 save 25 %

04 Apr 2016  |  Global

Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 26